ARTICLE | Company News
Orgenesis, Tel Hashomer deal
March 19, 2012 7:00 AM UTC
Tel Hashomer granted Orgenesis an exclusive license to develop and commercialize IP covering functional autologous insulin-producing cells (AIPC) regeneration technology as a therapy for diabetes. Tel...